title: Comparative effectiveness of dynamic treatment regimes: an application of the parametric g-formula.
abstract: Ideally, randomized trials would be used to compare the long-term effectiveness of dynamic treatment regimes on clinically relevant outcomes. However, because randomized trials are not always feasible or timely, we often must rely on observational data to compare dynamic treatment regimes. An example of a dynamic treatment regime is "start combined antiretroviral therapy (cART) within 6 months of CD4 cell count first dropping belowxcells/mm3or diagnosis of an AIDS-defining illness, whichever happens first" wherexcan take values between 200 and 500. Recently, Cain et al (2011) used inverse probability (IP) weighting of dynamic marginal structural models to find thexthat minimizes 5-year mortality risk under similar dynamic regimes using observational data. Unlike standard methods, IP weighting can appropriately adjust for measured time-varying confounders (e.g., CD4 cell count, viral load) that are affected by prior treatment. Here we describe an alternative method to IP weighting for comparing the effectiveness of dynamic cART regimes: the parametric g-formula. The parametric g-formula naturally handles dynamic regimes and, like IP weighting, can appropriately adjust for measured time-varying confounders. However, estimators based on the parametric g-formula are more efficient than IP weighted estimators. This is often at the expense of more parametric assumptions. Here we describe how to use the parametric g-formula to estimate risk by the end of a user-specified follow-up period under dynamic treatment regimes. We describe an application of this method to answer the "when to start" question using data from the HIV-CAUSAL Collaboration.
authors.forename: Jessica G
authors.initials: JG
authors.lastname: Young
authors.forename: Lauren E
authors.initials: LE
authors.lastname: Cain
authors.forename: James M
authors.initials: JM
authors.lastname: Robins
authors.forename: Eilis J
authors.initials: EJ
authors.lastname: O'Reilly
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Hernán
references.citation: Int J Biostat. 2007;3(1):Article 3
references.pmid: 19122793
references.citation: Biometrics. 2005 Dec;61(4):962-73
references.pmid: 16401269
references.citation: MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19
references.pmid: 1361652
references.citation: Stat Methods Med Res. 2012 Feb;21(1):31-54
references.pmid: 21030422
references.citation: Stat Med. 2007 Nov 10;26(25):4578-601
references.pmid: 17450501
references.citation: Int J Biostat. 2010;6(2):Article 8
references.pmid: 21969994
references.citation: Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):237-42
references.pmid: 16611197
references.citation: JAMA. 2010 Jul 21;304(3):321-33
references.pmid: 20639566
references.citation: Int J Biostat. 2010 Mar 03;6(2):Article 9
references.pmid: 20405047
references.citation: Lancet. 1998 Feb 21;351(9102):543-9
references.pmid: 9492772
references.citation: Int J Biostat. 2010;6(2):Article 2
references.pmid: 21969992
references.citation: Int J Biostat. 2010;6(2):Article 18
references.pmid: 21972433
references.citation: Lancet. 2007 Aug 4;370(9585):407-13
references.pmid: 17659333
references.citation: N Engl J Med. 1997 Sep 11;337(11):725-33
references.pmid: 9287227
references.citation: J Am Stat Assoc. 2001 Dec 1;96(456):1410-1423
references.pmid: 20019887
references.citation: AIDS. 2010 Jan 2;24(1):123-37
references.pmid: 19770621
references.citation: Int J Epidemiol. 2009 Dec;38(6):1599-611
references.pmid: 19389875
references.citation: Am J Epidemiol. 2003 Oct 1;158(7):687-94
references.pmid: 14507605
references.citation: Ann Intern Med. 2011 Apr 19;154(8):509-15
references.pmid: 21502648